Company intelligence / Profile preview

CreatSens Health

Tarragona, Tarragona, Spainrenalyse.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed a patented point-of-care diagnostic device ("Renalyse") that enables at-home monitoring of key kidney function biomarkers using a drop of blood. The system provides real-time data sharing with healthcare professionals via a cloud-connected platform. Clinical validation and certification are ongoing, with plans to launch commercially by around 2026. Early results support its utility in improving management and outcomes for CKD patients.

Therapeutic areas: CardiovascularNephrology
Modalities: DeviceDiagnostic device (Point-of-care technology)Nanotechnology-based sensorCloud-connected health platform
Industry: Metabolite Diagnostics

Partnerships

Mind the Gap program/Botín FoundationGENESIS VenturesEurostars program

Beyond the preview

Go deeper on CreatSens Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CreatSens Health.

Explore the full profile